SRF consolidated PAT up 31% YoY to ₹509 Cr on 35% revenue growth; margins ease from Q1's seasonal high
PAT +31.15% YoY · revenue +34.73% · margins compressing
₹4,904.2 Cr
+34.73% YoY
₹509.12 Cr
+31.15% YoY
10.33%
-0.3pp YoY
₹17.18
Consolidated revenue of ₹4,904 Cr grew 34.7% YoY and net profit of ₹509 Cr grew 31.2% YoY, with no exceptional items in either period so the growth is clean. Sequentially, after a seasonally strong Q1FY27 (revenue ₹5,033 Cr, PAT ₹759 Cr), the quarter eased 2.6% QoQ on revenue and 32.9% QoQ on PAT. Standalone PAT of ₹438.48 Cr grew a slower 20.9% YoY (vs consolidated's 31.2%) — a double-digit-point gap readers will see elsewhere; the consolidated print is the stronger and primary read.
Q2 FY-2027 vs prior quarters
Chemicals, standalone's largest segment, led growth — revenue up 23.9% YoY to ₹2,078 Cr and segment PBIT up 13.4% YoY to ₹538.85 Cr — running ahead of the 15-20% FY27 growth management guided after the Q1FY27 call. Technical Textiles segment profit jumped 71.2% YoY to ₹72.17 Cr on a 25.5% YoY revenue gain. Against this, consolidated net profit margin slipped to 10.3% from 15.0% in Q1FY27 and is roughly flat YoY (10.6%→10.3%), while the EBITDA-level margin on revenue from operations eased to ~19.3% from ~24.6% in Q1FY27 — Q1's margin strength looks like a seasonal (kharif/agrochemical-linked) peak rather than a step-change, making this quarter a normalization more than a deterioration.
The stock went into the print at ₹2,275.7, down 9.4% over the past month of trading.
What the summary numbers don't show
EPS: consolidated ₹17.18 (vs ₹13.10 YoY, ₹25.60 QoQ) — standalone ₹14.79 (vs ₹12.23 YoY, ₹19.10 QoQ).
FY27 capex INR1,500-2,000Cr for gas plants (Odisha). Pharma intermediate plant (INR180Cr) in 8 months. Specialty chemicals face Chinese pricing pressure but expect recovery.
— This quarter: met
No Q2FY27-specific street consensus for revenue/PAT turned up in search, so vsStreet is unknown rather than inferred. Against management's own Q1FY27-call commentary (sequential Q2/Q3 moderation in refrigerant volumes/pricing on seasonality, with YoY growth to stay strong, and 15-20% FY27 Chemicals growth), this print is on-plan: QoQ eased as flagged, YoY growth of 34.7%/31.2% held up, and Chemicals ran above its guided range. Separately, the company disclosed a ₹266.32 Cr GST show-cause notice on October 1, 2026; this filing's own notes carry no related provision, so the exposure is unresolved and unquantified in these numbers. A CHRO appointment and the Q3 board-meeting date are routine disclosures not tied to this quarter's print.
W1
Whether Chemicals sustains above-guidance growth after H1FY27's +23.1% YoY segment revenue (₹4,322 Cr) against the 15-20% FY27 guided range.
W2
Resolution and financial impact of the ₹266.32 Cr GST show-cause notice (Oct 1, 2026) — not yet provided for in these accounts.
W3
Whether consolidated NPM recovers from Q2's 10.3% (down from Q1's 15.0%) as the Odisha gas-plant capex (₹1,500-2,000 Cr guided for FY27) progresses.
No exceptional items in Q2FY27 or the Q2FY26 comparative quarter (FY26's ₹84.22/84.95 Cr New Labour Codes one-time impact was booked only in Q4FY26); three/four smaller overseas subsidiaries were reviewed by/not reviewed by other auditors per the limited review report but flagged immaterial.
Informational and educational content only. Not investment advice.